Korro Bio finance SVP sells 5 shares at $13.7

Korro Bio’s finance executive reported a small, pre-planned stock sale and continues to hold 16,241 unvested RSU-based shares.

Available on EDGAR 09/14/2026 - 04:06 PM EDT Accepted by SEC EDGAR 09/14/2026 - 04:05 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Korro Bio, Inc. (KRRO) reported that Senior Vice President, Finance Oliver Dolan sold 5 shares of common stock on September 11, 2026 at a weighted-average price of $13.716 per share, in transactions executed under a Rule 10b5-1 trading plan adopted on June 8, 2026. Following this sale, Dolan holds 16,241 shares directly, all issuable upon settlement of unvested RSUs scheduled to vest between December 15, 2026 and July 15, 2028, subject to a continuous Service Relationship.

Insider Trade Summary 10b5-1

Net Seller: 5 shares

Net Sell 1 txn

Insider Dolan Oliver

Role Senior Vice President, Finance

Sold 5 shs ($68.58)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2, F3	5	$13.716	$68.58

Holdings After Transaction: Common Stock — 16,241 shares (Direct)

Footnotes (3)

1. F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 8, 2026.
2. F2. The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions at prices ranging from $13.51 to $13.85, inclusive. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request.
3. F3. Includes 16,241 shares of common stock issuable upon settlement of restricted stock units (RSUs) that remain unvested, consisting of 10,741 shares that will vest on December 15, 2026, 2,750 shares that will vest on July 15, 2027, and 2,750 shares that will vest on July 15, 2028, in each case subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through each such date.

Key Figures

Shares sold: 5 shares Weighted-average sale price: $13.716 per share Sale price range: $13.51–$13.85 per share +5 more

8 metrics

Shares sold 5 shares Common stock sale on September 11, 2026

Weighted-average sale price $13.716 per share Common stock sold on September 11, 2026

Sale price range $13.51–$13.85 per share Prices for multiple sale transactions on September 11, 2026

Shares held after transaction 16,241 shares Direct holdings following reported sale, all issuable upon RSU settlement

RSUs vesting December 15, 2026 10,741 shares Unvested RSUs scheduled to vest on December 15, 2026

RSUs vesting July 15, 2027 2,750 shares Unvested RSUs scheduled to vest on July 15, 2027

RSUs vesting July 15, 2028 2,750 shares Unvested RSUs scheduled to vest on July 15, 2028

Rule 10b5-1 plan adoption date June 8, 2026 Trading plan under which the September 11, 2026 sale was effected

Key Terms

Rule 10b5-1 trading plan, weighted-average price, restricted stock units (RSUs), Service Relationship

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction was effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted-average price financial

"The price reported in Column 4 is a weighted-average price."

Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.

restricted stock units (RSUs) financial

"Includes 16,241 shares of common stock issuable upon settlement of restricted stock units (RSUs)"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

Service Relationship regulatory

"subject to the reporting person maintaining a continuous Service Relationship"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did KRRO report for Oliver Dolan?

Korro Bio reported that Oliver Dolan sold 5 shares of common stock on September 11, 2026 at a weighted-average price of $13.716 per share, executed under a Rule 10b5-1 trading plan.

At what price were the KRRO shares sold in this Form 4 filing?

The reported weighted-average sale price was $13.716 per share, with individual trade prices ranging from $13.51 to $13.85 per share, inclusive.

How many KRRO shares does Oliver Dolan hold after this transaction?

After the reported sale, Oliver Dolan holds 16,241 shares of Korro Bio common stock, all issuable upon settlement of restricted stock units (RSUs) that remain unvested.

What future vesting schedule is disclosed for Oliver Dolan’s KRRO RSUs?

The filing states that 10,741 shares vest on December 15, 2026, 2,750 shares on July 15, 2027, and 2,750 shares on July 15, 2028, each subject to maintaining a continuous Service Relationship.

Was the KRRO insider sale made under a Rule 10b5-1 plan?

Yes. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Oliver Dolan on June 8, 2026, and the plan status is also affirmed at the form level.

Does the Form 4 indicate any derivative transactions for KRRO?

No derivative securities transactions are reported. The filing shows only a single sale of 5 shares of common stock and discloses unvested RSUs as part of post-transaction holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dolan Oliver

(Last) (First) (Middle)

C/O KORRO BIO, INC.

60 FIRST STREET, 2ND FLOOR, SUITE 250

(Street)

CAMBRIDGE MASSACHUSETTS 02141

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Korro Bio, Inc. [ KRRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior Vice President, Finance

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2026		S(1)		5	D	$13.716(2)	16,241(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 8, 2026.

2. The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions at prices ranging from $13.51 to $13.85, inclusive. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request.

3. Includes 16,241 shares of common stock issuable upon settlement of restricted stock units (RSUs) that remain unvested, consisting of 10,741 shares that will vest on December 15, 2026, 2,750 shares that will vest on July 15, 2027, and 2,750 shares that will vest on July 15, 2028, in each case subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through each such date.

	/s/ Jeffrey Cerio, Attorney-in-fact	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)